Cargando…
Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-
BACKGROUND: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy (RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy. METHODS: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407329/ https://www.ncbi.nlm.nih.gov/pubmed/25896887 http://dx.doi.org/10.1186/s13014-015-0410-z |
_version_ | 1782367890450677760 |
---|---|
author | Umezawa, Rei Takanami, Kentaro Kadoya, Noriyuki Nakajima, Yujiro Saito, Masahide Ota, Hideki Matsushita, Haruo Sugawara, Toshiyuki Kubozono, Masaki Yamamoto, Takaya Ishikawa, Yojiro Takeda, Ken Taki, Yasuyuki Takase, Kei Jingu, Keiichi |
author_facet | Umezawa, Rei Takanami, Kentaro Kadoya, Noriyuki Nakajima, Yujiro Saito, Masahide Ota, Hideki Matsushita, Haruo Sugawara, Toshiyuki Kubozono, Masaki Yamamoto, Takaya Ishikawa, Yojiro Takeda, Ken Taki, Yasuyuki Takase, Kei Jingu, Keiichi |
author_sort | Umezawa, Rei |
collection | PubMed |
description | BACKGROUND: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy (RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy. METHODS: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with esophageal cancer before and six months after curative mediastinal RT. Single photon emission computed tomography (SPECT) images of pre-RT and post-RT were registered into RT dose distributions. The myocardium was contoured, and the regional RT dose was calculated. Normalization is required to compare pre- and post-RT SPECT images because the uptake pattern is changed due to the breathing level. Normalization was applied on the mean of SPECT counts in regions of the myocardium receiving less than 5 Gy. Relative values in each dose region (interval of 5 Gy) were calculated on the basis of this normalization for each patient. The reduction in the percent of relative values was calculated. RESULTS: Five patients were enrolled in this study. None of the patients had a past history of cardiac disease. The left ventricle was partially involved in RT fields in all patients. The patients received RT with median total doses of 60-66 Gy for the primary tumor and metastatic lymph nodes. Concomitant chemotherapy consisting of cisplatin or nedaplatin and 5-fluorouracil with RT was performed in 4 patients. All patients had reduced uptake corresponding to RT fields. Dose-effect relations for reduced uptake tended to be observed at 6 months after RT with mean decreases of 8.96% in regions at 10-15 Gy, 12.6% in regions at 20-25 Gy, 15.6% in regions at 30-35 Gy, 19.0% in regions at 40-45 Gy and 16.0% in regions at 50-55 Gy. CONCLUSIONS: Dose-effect relations for myocardial metabolic disorders tended to be observed. We may need to make an effort to reduce high-dose mediastinal RT to the myocardium in RT planning. |
format | Online Article Text |
id | pubmed-4407329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44073292015-04-24 Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- Umezawa, Rei Takanami, Kentaro Kadoya, Noriyuki Nakajima, Yujiro Saito, Masahide Ota, Hideki Matsushita, Haruo Sugawara, Toshiyuki Kubozono, Masaki Yamamoto, Takaya Ishikawa, Yojiro Takeda, Ken Taki, Yasuyuki Takase, Kei Jingu, Keiichi Radiat Oncol Research BACKGROUND: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy (RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy. METHODS: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with esophageal cancer before and six months after curative mediastinal RT. Single photon emission computed tomography (SPECT) images of pre-RT and post-RT were registered into RT dose distributions. The myocardium was contoured, and the regional RT dose was calculated. Normalization is required to compare pre- and post-RT SPECT images because the uptake pattern is changed due to the breathing level. Normalization was applied on the mean of SPECT counts in regions of the myocardium receiving less than 5 Gy. Relative values in each dose region (interval of 5 Gy) were calculated on the basis of this normalization for each patient. The reduction in the percent of relative values was calculated. RESULTS: Five patients were enrolled in this study. None of the patients had a past history of cardiac disease. The left ventricle was partially involved in RT fields in all patients. The patients received RT with median total doses of 60-66 Gy for the primary tumor and metastatic lymph nodes. Concomitant chemotherapy consisting of cisplatin or nedaplatin and 5-fluorouracil with RT was performed in 4 patients. All patients had reduced uptake corresponding to RT fields. Dose-effect relations for reduced uptake tended to be observed at 6 months after RT with mean decreases of 8.96% in regions at 10-15 Gy, 12.6% in regions at 20-25 Gy, 15.6% in regions at 30-35 Gy, 19.0% in regions at 40-45 Gy and 16.0% in regions at 50-55 Gy. CONCLUSIONS: Dose-effect relations for myocardial metabolic disorders tended to be observed. We may need to make an effort to reduce high-dose mediastinal RT to the myocardium in RT planning. BioMed Central 2015-04-21 /pmc/articles/PMC4407329/ /pubmed/25896887 http://dx.doi.org/10.1186/s13014-015-0410-z Text en © Umezawa et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Umezawa, Rei Takanami, Kentaro Kadoya, Noriyuki Nakajima, Yujiro Saito, Masahide Ota, Hideki Matsushita, Haruo Sugawara, Toshiyuki Kubozono, Masaki Yamamoto, Takaya Ishikawa, Yojiro Takeda, Ken Taki, Yasuyuki Takase, Kei Jingu, Keiichi Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
title | Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
title_full | Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
title_fullStr | Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
title_full_unstemmed | Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
title_short | Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
title_sort | assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study- |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407329/ https://www.ncbi.nlm.nih.gov/pubmed/25896887 http://dx.doi.org/10.1186/s13014-015-0410-z |
work_keys_str_mv | AT umezawarei assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT takanamikentaro assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT kadoyanoriyuki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT nakajimayujiro assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT saitomasahide assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT otahideki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT matsushitaharuo assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT sugawaratoshiyuki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT kubozonomasaki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT yamamototakaya assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT ishikawayojiro assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT takedaken assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT takiyasuyuki assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT takasekei assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy AT jingukeiichi assessmentofmyocardialmetabolicdisorderassociatedwithmediastinalradiotherapyforesophagealcancerapilotstudy |